Q3 2018 13F Holders as of 30 Sep 2018
-
Type / Class
-
Equity / ADR
-
Shares outstanding
-
55,574,229
-
Total 13F shares
-
40,188,306
-
Share change
-
+616,365
-
Total reported value
-
$2,847,498,166
-
Put/Call ratio
-
140%
-
Price per share
-
$70.86
-
Number of holders
-
94
-
Value change
-
+$44,455,447
-
Number of buys
-
49
-
Number of sells
-
43
Institutional Holders of Ascendis Pharma A/S - ADR (ASND) as of Q3 2018
As of 30 Sep 2018,
Ascendis Pharma A/S - ADR (ASND) was held by
94 institutional
shareholders
that filed Form 13F with the SEC.
Together, they reported ownership of
40,188,306 shares.
The largest 10 holders included
RA CAPITAL MANAGEMENT, LLC, ORBIMED ADVISORS LLC, FMR LLC, PRICE T ROWE ASSOCIATES INC /MD/, BAKER BROS. ADVISORS LP, Sofinnova Ventures Inc, Vivo Capital, LLC, venBio Select Advisor LLC, EVENTIDE ASSET MANAGEMENT, LLC, and FARALLON CAPITAL MANAGEMENT LLC.
This page lists
94
institutional shareholders reporting positions in this security
for the Q3 2018 filing period.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price
|
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.